Trial Profile

A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INCA 00186 (Primary) ; INCB 106385 (Primary) ; Retifanlimab (Primary)
Indications Adenocarcinoma; Anal cancer; Carcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Liver cancer; Mouth neoplasm; Oesophageal cancer; Oropharyngeal cancer; Pancreatic ductal carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Incyte Corporation

Most Recent Events

03 Jun 2025 Status changed from active, no longer recruiting to completed.
11 Jul 2023 Planned End Date changed from 11 Feb 2025 to 30 Jan 2024.
11 Jul 2023 Planned primary completion date changed from 11 Feb 2025 to 30 Jan 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com